dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: Arginase (type: enzyme)
Target: Arginase I

Ligand: 2(S)-amino-6-boronohexanoic acid (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.300000190734863 pKd
Reference (Journal): Inhibition of Mn2<sup>+</sup>2-Arginase by Borate Leads to the Design of a Transition State Analogue Inhibitor, 2(S)-Amino-6-boronohexanoic Acid.
Published in: J Am Chem Soc

Ligand: A1P (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 5.400000095367432 pKi
Reference (Journal): 2-aminoimidazole amino acids as inhibitors of the binuclear manganese metalloenzyme human arginase I.
Published in: J Med Chem

Ligand: A1P (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.699999809265137 pKd
Reference (Journal): 2-aminoimidazole amino acids as inhibitors of the binuclear manganese metalloenzyme human arginase I.
Published in: J Med Chem
Target family: Aryl hydrocarbon receptor (type: other_protein)
Target: Aryl hydrocarbon receptor

Ligand: TCDD (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: ezutromid (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.300000190734863 pKd
Reference (Journal): Chemical Proteomics and Phenotypic Profiling Identifies the Aryl Hydrocarbon Receptor as a Molecular Target of the Utrophin Modulator Ezutromid.
Published in: Angew Chem Int Ed Engl

Ligand: indole-3-carbinol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 4.570000171661377 pKd
Reference (Journal): Aromatic hydrocarbon responsiveness-receptor agonists generated from indole-3-carbinol in vitro and in vivo: comparisons with 2,3,7,8-tetrachlorodibenzo-p-dioxin.
Published in: Proc Natl Acad Sci USA

Ligand: indolo[3,2-b]carbazole (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 9.720000267028809 pKd
Reference (Journal): Aromatic hydrocarbon responsiveness-receptor agonists generated from indole-3-carbinol in vitro and in vivo: comparisons with 2,3,7,8-tetrachlorodibenzo-p-dioxin.
Published in: Proc Natl Acad Sci USA

Ligand: tapinarof (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (2022)
Primary target: yes
Median affinity:  pKd
Reference (Journal): Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans.
Published in: J Invest Dermatol
Target family: Atypical SLC22B subfamily (type: transporter)
Target: synaptic vesicle glycoprotein 2A

Ligand: levetiracetam (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1999), EMA (2000)
Primary target: yes
Median affinity: 5.800000190734863 pKi
Reference (Journal): The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes.
Published in: Eur J Pharmacol

Ligand: levetiracetam (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1999), EMA (2000)
Primary target: yes
Median affinity: 6.099999904632568 pIC50
Reference (Journal): Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity.
Published in: J Med Chem

Ligand: brivaracetam (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: EMA & FDA (2016)
Primary target: yes
Median affinity: 7 pIC50
Reference (Journal): Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity.
Published in: J Med Chem
Target family: Aurora kinase (Aur) family (type: enzyme)
Target: aurora kinase C

Ligand: AMG-900 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9 pIC50
Reference (Journal): Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.
Published in: Cancer Res

Ligand: BI-847325 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.820000171661377 pIC50
Reference (Journal): Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases.
Published in: Mol Cancer Ther

Ligand: compound 38 [PMID: 20817473] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.210000038146973 pIC50
Reference (Journal): Thieno[3,2-c]pyrazoles: a novel class of Aurora inhibitors with favorable antitumor activity.
Published in: Bioorg Med Chem

Ligand: danusertib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.210000038146973 pIC50
Reference (Journal): 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.
Published in: J Med Chem

Ligand: GSK1070916 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.819999694824219 pKi
Reference (Journal): Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase.
Published in: J Med Chem

Ligand: ilorasertib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9 pIC50
Reference (Journal): Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.
Published in: J Pharmacol Exp Ther

Ligand: MK-5108 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.920000076293945 pIC50
Reference (Journal): MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel.
Published in: Mol Cancer Ther

Ligand: SU6656 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.769999980926514 pIC50
Reference (Journal): The selectivity of protein kinase inhibitors: a further update.
Published in: Biochem J

Ligand: tozasertib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.34000015258789 pKi
Reference (Journal): VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo.
Published in: Nat Med
Target family: Aurora kinase (Aur) family (type: enzyme)
Target: aurora kinase B

Ligand: GSK2334470 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.5 pIC50
Reference (Journal): Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors.
Published in: J Med Chem
Target family: Autophagy receptors (type: other_protein)
Target: sequestosome 1

Ligand: YTK-2205 (Synthetic organic)
Interaction type: Agonist
Action: Activation
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Patent): Novel p62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies compring the same
Target family: Bacterial protein targets (type: other_protein)
Target: DNA gyrase subunit A

Ligand: ofloxacin (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: yes
Approval source: FDA (1990), UK (1992)
Primary target: no
Median affinity: 5.460000038146973 pIC50
Reference (Journal): Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser(83) and Asp(87).
Published in: Antimicrob Agents Chemother
Target family: Bacterial protein targets (type: other_protein)
Target: DNA gyrase

Ligand: BWC0977 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.399999618530273 pIC50
Target family: Bacterial protein targets (type: other_protein)
Target: polyketide synthase Pks13

Ligand: TAM16 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6.71999979019165 pIC50
Reference (Journal): Development of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13.
Published in: Cell
Target family: Bacterial protein targets (type: other_protein)
Target: DNA topoisomerase 4

Ligand: BWC0977 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8 pIC50
Target family: Bacterial protein targets (type: other_protein)
Target: DNA gyrase subunit B

Ligand: novobiocin (Natural product)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1964)
Primary target: no
Median affinity: 7.099999904632568 pIC50
Reference (Journal): Inhibition of DNA gyrase and DNA topoisomerase IV of Staphylococcus aureus and Escherichia coli by aminocoumarin antibiotics.
Published in: J Antimicrob Chemother

Ligand: cyclothialidine (Natural product)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: no
Primary target: no
Median affinity: 8.220000267028809 pKi
Reference (Journal): Mechanism of inhibition of DNA gyrase by cyclothialidine, a novel DNA gyrase inhibitor.
Published in: Antimicrob Agents Chemother

Ligand: cyclothialidine (Natural product)
Interaction type: None
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): A New-Class Antibacterial-Almost. Lessons in Drug Discovery and Development: A Critical Analysis of More than 50 Years of Effort toward ATPase Inhibitors of DNA Gyrase and Topoisomerase IV.
Published in: ACS Infect Dis
Target family: Bacterial protein targets (type: other_protein)
Target: DNA gyrase

Ligand: zoliflodacin (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Primary target: no
Median affinity: 6.769999980926514 pIC50
Reference (Patent): Compounds and methods for treating bacterial infections
Target family: Basic leucine zipper domain TFs (type: other_protein)
Target: nuclear factor, erythroid 2 like 2

Ligand: ML385 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors.
Published in: ACS Chem Biol

Ligand: omaveloxolone (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: yes
Approval source: FDA (2023)
Primary target: no
Median affinity:  -
Reference (Journal): Pharmacokinetics and pharmacodynamics of the novel Nrf2 activator omaveloxolone in primates.
Published in: Drug Des Devel Ther

Ligand: omaveloxolone (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: yes
Approval source: FDA (2023)
Primary target: no
Median affinity:  -
Reference (Journal): Omaveloxolone: an activator of Nrf2 for the treatment of Friedreich ataxia.
Published in: Expert Opin Investig Drugs
Target family: B-cell lymphoma 2 (Bcl-2) protein family (type: other_protein)
Target: Bcl-2-like 2

Ligand: venetoclax (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA and EMA (2016)
Primary target: no
Median affinity: 6.610000133514404 pKi
Reference (Journal): ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
Published in: Nat Med
Target family: B-cell lymphoma 2 (Bcl-2) protein family (type: other_protein)
Target: MCL1 apoptosis regulator, BCL2 family member

Ligand: AZD5991 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.699999809265137 pKi
Reference (Journal): Hot-Spots of Mcl-1 Protein.
Published in: J Med Chem

Ligand: obatoclax (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 5.539999961853027 pKi
Reference (Journal): Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.
Published in: Eur J Med Chem

Ligand: venetoclax (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA and EMA (2016)
Primary target: no
Median affinity: 6.349999904632568 pKi
Reference (Journal): ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
Published in: Nat Med
Target family: B-cell lymphoma 2 (Bcl-2) protein family (type: other_protein)
Target: Bcl-2-like 1

Ligand: foselutoclax (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Therapeutic targeting of cellular senescence in diabetic macular edema: preclinical and phase 1 trial results.
Published in: Nat Med
Target family: B-cell lymphoma 2 (Bcl-2) protein family (type: other_protein)
Target: BCL2 apoptosis regulator

Ligand: ABT-737 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9 pKi
Reference (Journal): Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
Published in: J Med Chem

Ligand: APG-1252-M1 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.350000381469727 pKi
Reference (Patent): Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells

Ligand: AZD4320 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.520000457763672 pIC50
Reference (Patent): Chemical compounds

Ligand: lisaftoclax (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 10 pKi
Reference (Journal): A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma.
Published in: Oncol Res

Ligand: navitoclax (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: yes
Median affinity: 9 pKi
Reference (Journal): Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.
Published in: J Med Chem

Ligand: obatoclax (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 5.960000038146973 pKi
Reference (Journal): Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.
Published in: Eur J Med Chem

Ligand: sonrotoclax (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 10.720000267028809 pIC50
Reference (Journal): Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2.
Published in: J Med Chem

Ligand: sonrotoclax (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.470000267028809 pIC50
Reference (Journal): Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2.
Published in: J Med Chem

Ligand: venetoclax (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA and EMA (2016)
Primary target: yes
Median affinity: 11 pKi
Reference (Journal): ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
Published in: Nat Med

Ligand: venetoclax (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA and EMA (2016)
Primary target: yes
Median affinity: 11 pKi
Reference (Patent): Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases.
Target family: B-cell lymphoma 2 (Bcl-2) protein family (type: other_protein)
Target: Bcl-2-like 1

Ligand: A-1331852 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.199999809265137 pEC50
Reference (Journal): Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL Inhibitor
Published in: ACS Med Chem Lett

Ligand: ABT-737 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.300000190734863 pKi
Reference (Journal): Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
Published in: J Med Chem

Ligand: APG-1252-M1 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.869999885559082 pKi
Reference (Patent): Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells

Ligand: AZD4320 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9 pIC50
Reference (Patent): Chemical compounds

Ligand: lisaftoclax (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.300000190734863 pKi
Reference (Journal): A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma.
Published in: Oncol Res

Ligand: navitoclax (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: yes
Median affinity: 9 pKi
Reference (Journal): Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.
Published in: J Med Chem

Ligand: obatoclax (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 5.329999923706055 pKi
Reference (Journal): Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.
Published in: Eur J Med Chem

Ligand: venetoclax (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA and EMA (2016)
Primary target: no
Median affinity: 7.320000171661377 pKi
Reference (Journal): ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
Published in: Nat Med
Target family: B-cell lymphoma 2 (Bcl-2) protein family (type: other_protein)
Target: Bcl-2-like 2

Ligand: ABT-737 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9 pKi
Reference (Journal): Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
Published in: J Med Chem
Target family: Beta-adrenergic receptor kinases (&beta;ARKs) (type: enzyme)
Target: beta adrenergic receptor kinase 2

Ligand: compound 101 [PMID: 21596927] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.489999771118164 pIC50
Reference (Journal): Molecular mechanism of selectivity among G protein-coupled receptor kinase 2 inhibitors.
Published in: Mol Pharmacol

Ligand: balanol (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.329999923706055 pIC50
Reference (Journal): Structure of human G protein-coupled receptor kinase 2 in complex with the kinase inhibitor balanol.
Published in: J Med Chem
Target family: Beta-adrenergic receptor kinases (&beta;ARKs) (type: enzyme)
Target: beta adrenergic receptor kinase 1

Ligand: compound 1o [PMID: 24210504] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.340000152587891 pIC50
Reference (Journal): Design and synthesis of novel 3-(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine derivatives as selective G-protein-coupled receptor kinase-2 and -5 inhibitors.
Published in: Bioorg Med Chem Lett

Ligand: compound 101 [PMID: 21596927] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.269999980926514 pIC50
Reference (Journal): Molecular mechanism of selectivity among G protein-coupled receptor kinase 2 inhibitors.
Published in: Mol Pharmacol

Ligand: CCG258747 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.739999771118164 pIC50
Reference (Journal): A New Paroxetine-Based GRK2 Inhibitor Reduces Internalization of the <i>μ</i>-Opioid Receptor.
Published in: Mol Pharmacol

Ligand: balanol (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.380000114440918 pIC50
Reference (Journal): Structure of human G protein-coupled receptor kinase 2 in complex with the kinase inhibitor balanol.
Published in: J Med Chem
Target family: &beta;-catenin destruction complex proteins (type: other_protein)
Target: axin 2

Ligand: CW85319 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 5.170000076293945 pKd
Reference (Journal): Pharmacological targeting of Axin2 suppresses cell growth and metastasis in colorectal cancer.
Published in: Br J Pharmacol
Target family: Blood coagulation components (type: enzyme)
Target: serpin family C member 1

Ligand: dalteparin (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: yes
Approval source: FDA (1994)
Primary target: yes
Median affinity:  -
Reference (Journal): Heparin and its low molecular weight derivatives: anticoagulant and antithrombotic properties.
Published in: Haemostasis